Health Condition 1: C53- Malignant neoplasm of cervix uteri
Conditions
Interventions
Intervention1: Not applicable: Not applicable
Sponsors
Tata Memorial Centre
Eligibility
Inclusion criteria
Inclusion criteria: Age >18 years with histopathologically confirmed upfront metastatic cervical patients or patients with cervical cancer who have become metastatic/recurred/progressed after prior concurrent chemo radiation or radiation.
Exclusion criteria
Exclusion criteria: a. Oligometastatic cervical cancer patients who are planned for treatment with curative intent. b. Patients treated with palliative radiotherapy only.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To estimate the progression-free survival, PFS of metastatic or recurrent cervical cancer patients treated with palliative systemic therapy in our institute from January 2015 to March 2020. The PFS will be from the date of start of palliative treatment till the date of progressionTimepoint: To estimate the progression-free survival, PFS of metastatic or recurrent cervical cancer patients treated with palliative systemic therapy in our institute from January 2015 to March 2020. The PFS will be from the date of start of palliative treatment till the date of progression | — |
Secondary
| Measure | Time frame |
|---|---|
| I. To estimate the Overall tumour response rates including stable disease, partial response, complete response and progressive disease. II. Toxicities of therapy: To study the toxicities and tolerance to chemotherapy/bevacizumab/immunotherapy. III. To estimate the overall survival of patients with metastatic stage IVB/recurrent/persistent cervical cancer patients treated at our institute with palliative systemic therapy from January 2015 to March 2020. Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactYogesh Kembhavi
Tata Memorial Centre
Outcome results
None listed